Have a feature idea you'd love to see implemented?
Let us know!
FULC Fulcrum Therapeutics Inc
Price (delayed)
$2.97
Market cap
$160.2M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.29
Enterprise value
$95.51M
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine
Highlights
Fulcrum Therapeutics's net income has soared by 82% YoY and by 11% from the previous quarter
The company's EPS has surged by 82% YoY and by 12% QoQ
Fulcrum Therapeutics's quick ratio has decreased by 17% from the previous quarter
The equity has contracted by 6% from the previous quarter
Key stats
What are the main financial stats of FULC
Market
Valuations
Earnings
Shares outstanding
53.94M
Market cap
$160.2M
Enterprise value
$95.51M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.72
Price to sales (P/S)
2.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.18
Revenue
$80.87M
EBIT
-$17.91M
EBITDA
-$16.18M
Free cash flow
-$8.74M
Per share
Balance sheet
Liquidity
EPS
-$0.29
Free cash flow per share
-$0.14
Book value per share
$4.12
Revenue per share
$1.3
TBVPS
$4.47
Total assets
$279.01M
Total liabilities
$21.72M
Debt
$9.15M
Equity
$257.29M
Working capital
$252.98M
Debt to equity
0.04
Current ratio
18.44
Quick ratio
18.06
Net debt/EBITDA
4
Margins
Efficiency
Dividend
EBITDA margin
-20%
Gross margin
100%
Net margin
-22.2%
Operating margin
-37.7%
Return on assets
-6.7%
Return on equity
-7.3%
Return on invested capital
-8.7%
Return on capital employed
-6.8%
Return on sales
-22.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FULC stock price
How has the Fulcrum Therapeutics stock price performed over time
Intraday
-0.67%
1 week
-10.54%
1 month
-15.38%
1 year
-32.35%
YTD
-56%
QTD
-16.81%
Financial performance
How have Fulcrum Therapeutics's revenue and profit performed over time
Revenue
$80.87M
Gross profit
$80.87M
Operating income
-$30.46M
Net income
-$17.91M
Gross margin
100%
Net margin
-22.2%
The net margin has soared by 99% YoY and by 10% from the previous quarter
Fulcrum Therapeutics's operating margin has soared by 99% YoY and by 6% from the previous quarter
Fulcrum Therapeutics's net income has soared by 82% YoY and by 11% from the previous quarter
The company's operating income has surged by 72% YoY and by 7% QoQ
Growth
What is Fulcrum Therapeutics's growth rate over time
Valuation
What is Fulcrum Therapeutics stock price valuation
P/E
N/A
P/B
0.72
P/S
2.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.18
The company's EPS has surged by 82% YoY and by 12% QoQ
FULC's P/B is 71% below its 5-year quarterly average of 2.5 and 58% below its last 4 quarters average of 1.7
The equity has contracted by 6% from the previous quarter
The price to sales (P/S) is 98% lower than the last 4 quarters average of 97.0 and 97% lower than the 5-year quarterly average of 79.0
Efficiency
How efficient is Fulcrum Therapeutics business performance
The company's return on sales has surged by 99% YoY and by 10% QoQ
Fulcrum Therapeutics's ROE has soared by 81% YoY and by 12% from the previous quarter
Fulcrum Therapeutics's ROA has soared by 81% YoY and by 12% from the previous quarter
FULC's return on invested capital has surged by 78% year-on-year and by 6% since the previous quarter
Dividends
What is FULC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FULC.
Financial health
How did Fulcrum Therapeutics financials performed over time
Fulcrum Therapeutics's quick ratio has decreased by 17% from the previous quarter
The current ratio has declined by 16% since the previous quarter
The debt is 96% less than the equity
The debt has contracted by 20% YoY and by 5% from the previous quarter
The equity has contracted by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.